Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Widely Inclusive, Hybrid-Decentralized Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS

NCT07589764 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT07589764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07589764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Widely Inclusive, Hybrid-Decentralized Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS
Lead sponsor
Duke University
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
October 1, 2027
Enrollment
100 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis als